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Introduction 
Health technology assessment is a widely used methodology for informing payers about the value of 
health care interventions.  Its prominence within decision making has grown by its adoption by 
reimbursement bodies around the world.1  Despite this prominence, its impact on clinical practice 
remains highly variable, especially within publically funded health systems.  For instance, several 
studies within the United Kingdom have identified low uptake of recommendations by the National 
Institute for Health and Care Excellence (NICE).2-5  
The notion of slow diffusion is not new.6  Neither is knowledge about the effectiveness of 
interventions to improve implementation.7  Information about the cost-effectiveness of these 
interventions has been less well developed, with early attempts being very simplistic.7  
In this paper, I outline a new economic framework that seeks to estimate the value realised to 
payers when health technologies are implemented appropriately; this value could be in the form of 
lives saved or quality of life gains.  The value of these realised gains is termed the value of 
implementation (VOImp).  Two case studies are then presented that highlight how the VOImp 
framework can be used.  Further work which has incorporated more realistic features relating to the 
dynamics of diffusion and reimbursement processes is also introduced.  Lessons that this literature 
provides for payers and manufacturers is then outlined.  The paper ends with a short discussion and 
a conclusion as to the relevance of this work to payers and manufacturers. 
The work presented in this paper is based on standard methods and decision rules associated with 
economic evaluation in healthcare.8  Specifically, cost-effectiveness is measured by an incremental 
cost-effectiveness ratio (ICER), with the measure of effectiveness being the quality adjusted life year 
(QALY).  Decisions about whether a technology is cost-effective are made by comparing the ICER to a 
threshold value for a QALY gained.  This threshold value represents the maximum price a payer can 
spend on a QALY in order that the gains from adopting the new technology are greater than the 
potential gains from alternative uses of the same investment.  If an ICER is greater than the 
threshold value, this suggests that investing in alternative uses would generate more QALYs, i.e. the 
new technology is not cost-effective and should not be funded.  Of note is that this threshold varies 
between countries, principally due to different funding levels. 
The paper is not written for, not its conclusions restricted to, any specific health system.  However, 
the use of economic evaluation in the form summarised above is more closely aligned to the notion 
of payers seeking health maximisation within a fixed budget.  As such, the paper is most relevant to 
publicly funded health systems. 
Valuing implementation 
A major step forward in our assessment of the value of implementation initiatives was developed by 
Fenwick and colleagues in 2008.9  Their work was the first to link the value of implementation to the 
value of information (VOI), which had already been demonstrated as being important to decision 
makers.10  In the VOI approach, an estimate is made of the losses associated with the current 
estimate of cost-effectiveness potentially being wrong due to the imprecision of its constituent 
parameters.  For example, the analysis may conclude that technology is cost-effectiveness, but with 
perfect information, the analysis could show that it is not cost-effective.  Knowing the value of this 
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perfect information is a useful starting point for decisions about whether to collect more 
information (which leads to improvements in the precision of our estimates). 
A major weakness of the VOI approach is that it assumes that all the estimated benefits of the health 
technology are fully realised; in other words, it assumes perfect implementation.  Adding 
implementation into this framework allows us to estimate an expected value of implementation, 
which can be interpreted as the amount of money we can invest in an implementation initiative 
before it is no longer cost-effective to do so.  In its most basic form, the value of implementation is 
the net monetary benefit of the technology (which is another way of expressing the ICER), multiplied 
by the uptake of the technology.  Linking VOI and VOImp allows the joint consideration of evidence 
generation, implementation and their associated uncertainties. 
 
Extensions to the VOImp framework 
The incorporation of patient sub-groups 
Faria and colleagues introduced one important extension to the framework developed by Fenwick; 
comparing the value of implementation across patient subgroups.11  The work used evidence from 
the NICE Technology Appraisal of dabigatran etexilate for the prevention of stroke and systemic 
embolism in atrial fibrillation.12  Their study evaluated a 5% improvement in absolute uptake, costing 
£3.66 million nationally. 
Based on the NICE cost-effectiveness threshold of £20,000, the assessed implementation activity 
generates £1.42 million (or 71 QALYs) of benefit to England and Wales per annum.11  However, these 
results mask a huge disparity in the cost-effectiveness of using dabigatran in different patient 
populations. Importantly, investing in implementation was not cost-effective for severe patient 
subgroups, even though dabigatran is more cost-effective in these groups.  The reason for this result 
was that the cost of the intervention were fixed, regardless of the population size, so whilst 
dabigatran was more cost-effective in the severe patient population, the cost of increasing uptake 
were greater than the health benefits it produced .  When this same cost was spread across a bigger 
patient population the value to the payer was higher. 
The incorporation of diffusion dynamics 
Whyte and colleagues developed the VOImp framework by undertaking a multi-period analysis that 
included dynamic diffusion for both the intervention and the baseline.13  The dynamics used s-
shaped diffusion curves which were fitted to available data.6  The analysis used the NICE analysis of 
natriuretic peptide testing for suspected heart failure, with a 5% improvement in absolute uptake for 
a national cost of £28,186.14 
Based on a cost-effectiveness threshold of £20,00 the modelled activity had a value of £15,915,094 
over a 10 year period.13  Importantly, the vast majority of this value was within the first five years of 
the modelled period as the utilisation rates with and without the implementation activity were close 
to 100% at this point (due to natural diffusion in the absence of the initiative). 
The impact of evidence on the value of implementation 
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Grimm and colleagues examined the potential effect that improved evidence relating to clinical 
effectiveness may have on implementation.15  This work examined a screening technology for 
preterm birth.  Two potential research studies were then considered; a diagnostic accuracy study 
which assesses the accuracy of the screening technology and a randomised controlled trial which 
jointly assesses the effectiveness of the screen and subsequent treatment. 
Diffusion curves associated with the two research studies were generated through elicitation of 
expert beliefs.16  The experts considered the trial to produce more convincing evidence which would 
generate faster and higher levels of diffusion.  This, in turn, increased the expected value of the trial 
as its associated recommendations were realised by a greater proportion of the eligible patient 
population. 
The impact of price changes on the value of implementation 
In a further extension, Grimm and colleagues examined the ways in which implementation can alter 
the cost-effectiveness of the underlying health technology.17  Their work examined the possibility 
that the wider use of a technology can produce lower prices due to increased competition between 
manufacturers and/or economics of scale. 
Evidence of this effect has been widely examined in non-medical markets and this general 
relationship can be parameterised in the form of experience curves which describe price as a 
function of sales volume.18  Incorporation of this experience curve effect into the same preterm birth 
evaluation described earlier demonstrated an increased value of any intervention that increased 
implementation (due to the associated price reductions making the technology more cost-effective). 
 
Lessons for payers and manufacturers 
The developments in assessing the value of implementation seen in the last 10 years have improved 
our understanding of how to assess value.  From this growing body of work, we are able to distil 
some important lessons for payers and manufacturers.  These lessons can be quantified by the 
application of the framework.  Such analyses can be complex, however, the same lessons can be 
considered qualitatively in decisions relating to research design, reimbursement and investment in 
implementation initiatives.  
Lesson 1: pricing up to the threshold provides no incentive for payers to invest in implementation 
If a manufacturer prices a new technology such that the ICER is equal to the funding threshold, there 
is no incentive for the payer to invest in implementation. This is because, by definition, when a 
ƚĞĐŚŶŽůŽŐǇ ?Ɛ/ZŝƐĞƋƵĂůƚŽƚŚĞƚŚƌĞƐŚŽůĚ ?ŝƚƐďĞŶĞĨŝƚƐĂƌĞ equal to its opportunity costs, 
consequently, so any further expenditure relating to the technology is not worthwhile. 
Lesson 2: the value of implementation is generally greater for larger populations and more cost-
effective technologies 
As the value of implementation is estimated as the net monetary benefit of the new technology 
multiplied by the patient population, this lesson is obvious.  However, when identifying 
opportunities to invest in implementation initiatives, these need to be considered simultaneously.  
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The study by Faria and colleagues on dabigatran showed that surprising results can be produced; a 
population which was most cost-effective to treat was not the best investment opportunity because 
the costs required to increase implementation were in relation to a small number of patients.11  
Lesson 3: naturally fast-diffusing technologies provide a reduced incentive to invest in 
implementation 
For technologies that are expected to rapidly diffuse without additional investment, the scope for 
further improvement is reduced as the upper limit on diffusion is quickly hit.  Identifying these 
technologies can be difficult because whilst there is evidence that highlights general factors 
associated with rapid diffusion, such as lack of safety concerns or lack of alternative treatments, 
context-specific factors are clearly important.19  The flip side of this argument is that for technologies 
with expected slow diffusion, investment is required to generate more extensive health gains, which 
in turn requires the technology to be priced sufficiently below the threshold to incentivise 
investment. 
Lesson 4: diffusion generates further evidence 
The more a technology is used, the more is learnt about it.  Such evidence can be anecdotal and 
piecemeal (e.g., case series), or it can be more formal (e.g., disease registries).  This evidence is of 
value to payers if it allows the uncertainty relating to the funding decision to be reduced.  Managed 
access schemes, whereby reimbursement is granted in exchange for further data collection,can be 
useful for gathering this evidence. 
Lesson 5: better evidence can generate higher implementation 
The study by Grimm and colleagues showed that better quality evidence was thought by experts to 
produce quicker and higher levels of implementation.  As such, better research design not only 
improves the reimbursement decision by reducing uncertainty, it can increase the value of 
implementation.  Once again, carefully designed managed access schemes can be useful in 
generating this evidence.  This raises the possibility that a managed access scheme which collected 
data that resolved an important issue, could end up producing higher levels of implementation in 
the long run than if unfettered access had been granted.  This is because without the collection of 
ĚĂƚĂ ?ƚŚĞƵŶƌĞƐŽůǀĞĚƵŶĐĞƌƚĂŝŶƚǇĐŽƵůĚůŝŵŝƚĐůŝŶŝĐŝĂŶƐ ?ĚĞƐŝƌĞƚŽƵƐĞƚŚĞŶĞǁƚĞĐŚŶŽůŽŐǇ. 
Lesson 6: get the funding threshold right 
It is of fundamental importance to note that the analyses described here are reliant on having a 
robust cost-effectiveness threshold. From an economic perspective, that threshold should represent 
the opportunity costs of investing in a new technology.  However, evidence suggests that the 
thresholds used across the world are underestimating opportunity costs.20,21  This means that the 
value of new health technologies is being overestimated, which in turn, means that the value of 
implementing those technologies will be overestimated. 
While this finding does not affect the lessons above, any quantitative assessment of the cost-
effectiveness of implementation strategies could be seriously flawed.  Consequently, if faced with 
value of implementation analyses, decision makers should ensure that the results are subjected to 
sensitivity analyses in relation to the value of the threshold. 
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Discussion 
This paper sets out a framework for assessing the value of implementation and recent developments 
that have generated a more realistic representation of implementation dynamics.  With the help of 
case studies that have used this framework, useful qualitative lessons have been identified for 
payers and manufacturers. 
The main strength of this framework and paper is its alignment with the standard methods of 
economic evaluation that are widely used in reimbursement agencies across the world.1  This 
strength also suggests its main weakness; not all reimbursement agencies adopt cost-utility analysis 
or apply an explicit funding threshold.22,23   
The use of other methods of economic eǀĂůƵĂƚŝŽŶĚŽĞƐŶ ?ƚŶĞĐĞƐƐĂƌŝůǇŝŶǀĂůŝĚĂƚĞƚŚĞĂŶĂůǇƐŝƐĂďŽǀĞ ?
The lessons were deliberately constructed to avoid specific methodological detail, such as QALYs.  
However, it does require opportunity cost  to be considered in a way that the objective function of 
the decision maker is maximised.  In the language of cost-effectiveness analysis, this relates to the 
use of a funding threshold at the correct level.  As such, the relevance of the framework is diluted for 
processes that pay little attention to cost constraints, have ill-defined decision making criteria or are 
primarily driven by extraneous personal, social or political goals.24  
 
Conclusion 
Too much attention is currently ďĞŝŶŐƉĂŝĚƚŽ ‘ŐĞƚƚŝŶŐĂƉŽƐŝƚŝǀĞƌĞŝŵďƵƌƐĞŵĞŶƚĚĞĐŝƐŝŽŶ ?ĂŶĚĂƐĂ
consequence, implementation of guidance is  well below what is possible.  This results in a huge loss 
of value to society.  Issues relating to implementation need to be central to the considerations of 
payers and manufacturers.  Payers need to consider identifying and investing in implementation 
activities for each set of guidance they issue.  Manufacturers need to consider implementation in the 
design of their clinical studies and set their prices to give payers a margin to invest in 
implementation.  The sooner the two camps recognise their symbiotic relationship in realising value, 
the quicker they can act in a way that is mutually beneficial. 
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